	US 12,467,043 B2
	3′ UTR CRISPR-DCAS 13 engineering system and methods of using same
Qianben Wang, Durham, NC (US); Fuwen Yuan, Durham, NC (US); and Wei Li, Irvine, CA (US)
Assigned to Duke University, Durham, NC (US); and Baylor College of Medicine, Houston, TX (US)
Appl. No. 17/626,561
Filed by DUKE UNIVERSITY, Durham, NC (US); and BAYLOR COLLEGE OF MEDICINE, Houston, TX (US)
PCT Filed Jul. 13, 2020, PCT No. PCT/US2020/041840 § 371(c)(1), (2) Date Jan. 12, 2022, PCT Pub. No. WO2021/011493, PCT Pub. Date Jan. 21, 2021.
Claims priority of provisional application 62/873,270, filed on Jul. 12, 2019.
Prior Publication US 2022/0403356 A1, Dec. 22, 2022
Int. Cl. C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01)

CPC C12N 9/22 (2013.01) [C12N 15/11 (2013.01); C12N 15/1135 (2013.01); C12N 2310/14 (2013.01); C12N 2310/20 (2017.05)]

22 Claims

1. A system for modifying the length of a 3′ untranslated region (UTR) of an mRNA transcript, the system comprising one or more nucleic acid molecules comprising:

(i) a nucleic acid sequence encoding a direct repeat RNA sequence that can bind a catalytically dead Cas13;

(ii) a nucleic acid sequence encoding a guide RNA (gRNA) sequence that can bind to a target site that is proximal and/or distal to a polyadenylation site (PAS) of the 3′ UTR of the mRNA transcript; and

(iii) a nucleic acid sequence encoding a catalytically dead Cas13, wherein the system causes modification of the length of the 3′ untranslated region (UTR) of an mRNA transcript,

wherein the one or more nucleic acids molecules are contained in one or more vectors and wherein the vector comprises the nucleic acid sequence set forth in SEQ ID NO: 02.